A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

This study is testing a combination of three treatments — apatinib (an anti-angiogenic drug that cuts off blood supply to tumours), adebrelimab (an immunotherapy drug), and chemotherapy — in patients with intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts inside the liver) that cannot be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have biopsy-confirmed intrahepatic cholangiocarcinoma (ICC) that cannot be removed by surgery or has come back after surgery - You have not had any prior systemic (whole-body) treatment for advanced ICC (except chemotherapy more than 6 months after a curative surgery) - Any prior local treatments (e.g., radiation, ablation) were completed at least 4 weeks ago **You may NOT be eligible if...** - Your cancer has already been treated with systemic therapy - You have severe liver or organ failure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.